» Articles » PMID: 37232807

Surgical Management of Retroperitoneal Sarcoma

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2023 May 26
PMID 37232807
Authors
Affiliations
Soon will be listed here.
Abstract

Surgery is the cornerstone of treatment for retroperitoneal sarcoma (RPS). Surgery should be performed by a surgical oncologist with sub-specialization in this disease and in the context of a multidisciplinary team of sarcoma specialists. For primary RPS, the goal of surgery is to achieve the complete en bloc resection of the tumor along with involved organs and structures to maximize the clearance of the disease. The extent of resection also needs to consider the risk of complications. Unfortunately, the overarching challenge in primary RPS treatment is that even with optimal surgery, tumor recurrence occurs frequently. The pattern of recurrence after surgery (e.g., local versus distant) is strongly associated with the specific histologic type of RPS. Radiation and systemic therapy may improve outcomes in RPS and there is emerging data studying the benefit of non-surgical treatments in primary disease. Topics in need of further investigation include criteria for unresectability and management of locally recurrent disease. Moving forward, global collaboration among RPS specialists will be key for continuing to advance our understanding of this disease and find more effective treatments.

Citing Articles

Retroperitoneal leiomyosarcoma mimicking an ovarian tumor diagnosed using a negative ovarian pedicle sign.

Mitsuo K, Kaneko H, Tsukamoto M, Asami Y, Miyazawa A, Miyashita K Radiol Case Rep. 2024; 19(8):3429-3433.

PMID: 38872746 PMC: 11169071. DOI: 10.1016/j.radcr.2024.04.066.


Resection of previously inoperable retroperitoneal liposarcoma.

Maclean E, Delriviere L, Johansson M, Hodder R BMJ Case Rep. 2023; 16(11).

PMID: 37945281 PMC: 10649782. DOI: 10.1136/bcr-2023-256479.

References
1.
Ruspi L, Cananzi F, Aymerito F, Sicoli F, Sama L, Vanni E . Measuring the impact of complications after surgery for retroperitoneal sarcoma: Is comprehensive complication index better than Clavien-Dindo Classification?. Eur J Surg Oncol. 2021; 48(5):978-984. DOI: 10.1016/j.ejso.2021.12.010. View

2.
Squires M, Ethun C, Donahue E, Benbow J, Anderson C, Jagosky M . A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma. J Surg Oncol. 2021; 124(5):829-837. DOI: 10.1002/jso.26586. View

3.
Callegaro D, Raut C, Swallow C, Gronchi A . Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program. Curr Opin Oncol. 2021; 33(4):301-308. DOI: 10.1097/CCO.0000000000000746. View

4.
Tirotta F, Parente A, Richardson T, Almonib A, Evenden C, Almond L . Comparison of comprehensive complication index and Clavien-Dindo classification in patients with retroperitoneal sarcoma. J Surg Oncol. 2021; 124(7):1166-1172. DOI: 10.1002/jso.26612. View

5.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M . A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113(3):573-81. DOI: 10.1002/cncr.23592. View